CVS Health Corp vs Kohl's Corporation — how do they compare? CVS Health Corp trades at $86.3 (market cap $112.49B), while Kohl's Corporation trades at $20.09 (market cap $2.28B). The key difference: CVS Health Corp is far larger — about 49.3× Kohl's Corporation's market cap, and CVS Health Corp pays the higher dividend (3.02%). Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and Kohl's Corporation for 48 Days on average.
| CVS | KSS | |
|---|---|---|
Market Cap | $112.49B | $2.28B |
Volume | 8,467,392 | 5,033,684 |
Sector | Health | Consumer Cyclical |
52-Week High | $110.60 | $24.71 |
52-Week Low | $70.08 | $11.72 |
Typical Hold Time | 83 Days | 48 Days |
Enterprise Value | $174.83B | $7.88B |
Dividend Yield | 3.02% | 2.49% |
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.80, up 1.59% today, with strong analyst support (85% buy ratings) and a $111.20 consensus price target suggesting 27% upside. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $2.58 surpassing the $1.87 estimate. Revenue growth remains solid, reaching $402.07B in 2025, though net margins compressed to 1.18%. The technical picture shows bullish momentum with current price near key support at $87.
CVS presents a compelling value opportunity with attractive valuation multiples (P/E 23.21, P/S 0.27) and dividend stability, but faces margin pressure from healthcare cost trends. The stock's upside depends on maintaining earnings momentum amid reimbursement challenges and regulatory scrutiny highlighted in recent legal investigations.
Kohl's (KSS) trades at $20.10, up 2.39% with bullish technical momentum despite recent earnings beats showing mixed fundamentals. The company reported three consecutive quarterly earnings beats but faces declining revenue trends from $16.22B in 2025 to projected $15.4B in 2026. Valuation metrics appear attractive with P/E of 8.64 and P/B of 0.55, while technical indicators show strong bullish moving average signals but overbought RSI conditions.
KSS presents a value opportunity with deep discount valuations but carries execution risks amid persistent sales declines. The stock's 15.6% three-month rally faces sustainability questions as consumer spending shifts toward essentials. Analyst consensus remains cautious with 50% hold ratings and $15.50 price target below current levels, reflecting concerns about holiday execution and margin preservation.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →Kohl's operates 1,165 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also operates a large digital sales business. Women's apparel is Kohl's largest category, having generated 27% of its 2021 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.
Read more on KSS →